Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave
The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated so...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2022-12, Vol.22 (12), p.3130-3136 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3136 |
|---|---|
| container_issue | 12 |
| container_start_page | 3130 |
| container_title | American journal of transplantation |
| container_volume | 22 |
| creator | Al Jurdi, Ayman Morena, Leela Cote, Mariesa Bethea, Emily Azzi, Jamil Riella, Leonardo V. |
| description | The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre‐exposure prophylaxis and 222 vaccine‐matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS‐CoV‐2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p |
| doi_str_mv | 10.1111/ajt.17128 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9906353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2679703086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4438-4b50e13ea1d2ffa2b2d1149fb565ac5897f69143f2bb992f8fa367838dd1bcb3</originalsourceid><addsrcrecordid>eNp1ks2O0zAQxyMEYpeFAy-ALHGBQ7f-SBzngrRa8amVuPRu2c44cTe1g5203RuPwJPwUDwJpl0qQMKy5Bn557_-M56ieE7wJclrqdbTJakJFQ-Kc8IxXnBSsoenmFVnxZOU1hiTmgr6uDhjVU3rhvDz4vvK7VUHW7dRemnc0KlDiMYIP75-g_0Y0hwhp2Hs7wa1dwnlrVIKxqkJWrRzU4-GsIOIdAR1O_UxzF2PnLdgJhc8ii7d5hRtlTHOHx6lMLgWhdgpj6aofBoH5ScUwbjRgZ8SaufofIemHlDYOBOzzk5t4WnxyKohwbP786JYvXu7uv6wuPn8_uP11c3ClCUTi1JXGAgDRVpqraKatoSUjdUVr5SpRFNb3uQeWap101ArrGK8Fky0LdFGs4vizVF2nPUGWpMtRTXIMebexDsZlJN_33jXyy5sZdNgziqWBV7dC8TwZYY0yY1LBoZcJoQ5ScrrpsYMC57Rl_-g6zBHn6uTtC5LjkVViky9PlK5FSlFsCczBMtfQyDzEMjDEGT2xZ_uT-TvX8_A8gjs3AB3_1eSV59WR8mfEJLDbw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2744608548</pqid></control><display><type>article</type><title>Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Al Jurdi, Ayman ; Morena, Leela ; Cote, Mariesa ; Bethea, Emily ; Azzi, Jamil ; Riella, Leonardo V.</creator><creatorcontrib>Al Jurdi, Ayman ; Morena, Leela ; Cote, Mariesa ; Bethea, Emily ; Azzi, Jamil ; Riella, Leonardo V.</creatorcontrib><description>The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre‐exposure prophylaxis and 222 vaccine‐matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS‐CoV‐2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p < .001). In the tixagevimab/cilgavimab group, SOTRs who received the 150–150 mg dose had a higher incidence of breakthrough infections compared to those who received the 300–300 mg dose (p = .025). Adverse events were uncommon, occurring in 4% of our cohort and most were mild. There was no significant change in serum creatinine or liver chemistries in kidney and liver transplant recipients, respectively. In conclusion, we found that tixagevimab/cilgavimab use is safe and associated with a lower risk of breakthrough SARS‐CoV‐2 infection in vaccinated solid organ transplant recipients during the Omicron wave.
A retrospective matched cohort study shows that tixagevimab‐cilgavimab pre‐exposure prophylaxis in vaccinated solid organ transplant recipients is associated with a lower risk of breakthrough SARS‐CoV‐2 infection during the Omicron wave.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.17128</identifier><identifier>PMID: 35727916</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Antibodies, Monoclonal ; Brief Communication ; COVID-19 ; Creatinine ; Disease prevention ; Humans ; Infections ; kidney transplant ; Kidney transplantation ; Kidney transplants ; Liver transplantation ; Monoclonal antibodies ; Organ Transplantation - adverse effects ; Pre-Exposure Prophylaxis ; Prophylaxis ; Retrospective Studies ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Transplant Recipients</subject><ispartof>American journal of transplantation, 2022-12, Vol.22 (12), p.3130-3136</ispartof><rights>2022 The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><rights>2022 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>Copyright © 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved. 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4438-4b50e13ea1d2ffa2b2d1149fb565ac5897f69143f2bb992f8fa367838dd1bcb3</citedby><cites>FETCH-LOGICAL-c4438-4b50e13ea1d2ffa2b2d1149fb565ac5897f69143f2bb992f8fa367838dd1bcb3</cites><orcidid>0000-0002-7636-3196 ; 0000-0002-7652-3399 ; 0000-0002-6909-4645</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.17128$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.17128$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35727916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Jurdi, Ayman</creatorcontrib><creatorcontrib>Morena, Leela</creatorcontrib><creatorcontrib>Cote, Mariesa</creatorcontrib><creatorcontrib>Bethea, Emily</creatorcontrib><creatorcontrib>Azzi, Jamil</creatorcontrib><creatorcontrib>Riella, Leonardo V.</creatorcontrib><title>Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre‐exposure prophylaxis and 222 vaccine‐matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS‐CoV‐2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p < .001). In the tixagevimab/cilgavimab group, SOTRs who received the 150–150 mg dose had a higher incidence of breakthrough infections compared to those who received the 300–300 mg dose (p = .025). Adverse events were uncommon, occurring in 4% of our cohort and most were mild. There was no significant change in serum creatinine or liver chemistries in kidney and liver transplant recipients, respectively. In conclusion, we found that tixagevimab/cilgavimab use is safe and associated with a lower risk of breakthrough SARS‐CoV‐2 infection in vaccinated solid organ transplant recipients during the Omicron wave.
A retrospective matched cohort study shows that tixagevimab‐cilgavimab pre‐exposure prophylaxis in vaccinated solid organ transplant recipients is associated with a lower risk of breakthrough SARS‐CoV‐2 infection during the Omicron wave.</description><subject>Antibodies, Monoclonal</subject><subject>Brief Communication</subject><subject>COVID-19</subject><subject>Creatinine</subject><subject>Disease prevention</subject><subject>Humans</subject><subject>Infections</subject><subject>kidney transplant</subject><subject>Kidney transplantation</subject><subject>Kidney transplants</subject><subject>Liver transplantation</subject><subject>Monoclonal antibodies</subject><subject>Organ Transplantation - adverse effects</subject><subject>Pre-Exposure Prophylaxis</subject><subject>Prophylaxis</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Transplant Recipients</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ks2O0zAQxyMEYpeFAy-ALHGBQ7f-SBzngrRa8amVuPRu2c44cTe1g5203RuPwJPwUDwJpl0qQMKy5Bn557_-M56ieE7wJclrqdbTJakJFQ-Kc8IxXnBSsoenmFVnxZOU1hiTmgr6uDhjVU3rhvDz4vvK7VUHW7dRemnc0KlDiMYIP75-g_0Y0hwhp2Hs7wa1dwnlrVIKxqkJWrRzU4-GsIOIdAR1O_UxzF2PnLdgJhc8ii7d5hRtlTHOHx6lMLgWhdgpj6aofBoH5ScUwbjRgZ8SaufofIemHlDYOBOzzk5t4WnxyKohwbP786JYvXu7uv6wuPn8_uP11c3ClCUTi1JXGAgDRVpqraKatoSUjdUVr5SpRFNb3uQeWap101ArrGK8Fky0LdFGs4vizVF2nPUGWpMtRTXIMebexDsZlJN_33jXyy5sZdNgziqWBV7dC8TwZYY0yY1LBoZcJoQ5ScrrpsYMC57Rl_-g6zBHn6uTtC5LjkVViky9PlK5FSlFsCczBMtfQyDzEMjDEGT2xZ_uT-TvX8_A8gjs3AB3_1eSV59WR8mfEJLDbw</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Al Jurdi, Ayman</creator><creator>Morena, Leela</creator><creator>Cote, Mariesa</creator><creator>Bethea, Emily</creator><creator>Azzi, Jamil</creator><creator>Riella, Leonardo V.</creator><general>Elsevier Limited</general><general>American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7636-3196</orcidid><orcidid>https://orcid.org/0000-0002-7652-3399</orcidid><orcidid>https://orcid.org/0000-0002-6909-4645</orcidid></search><sort><creationdate>202212</creationdate><title>Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave</title><author>Al Jurdi, Ayman ; Morena, Leela ; Cote, Mariesa ; Bethea, Emily ; Azzi, Jamil ; Riella, Leonardo V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4438-4b50e13ea1d2ffa2b2d1149fb565ac5897f69143f2bb992f8fa367838dd1bcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal</topic><topic>Brief Communication</topic><topic>COVID-19</topic><topic>Creatinine</topic><topic>Disease prevention</topic><topic>Humans</topic><topic>Infections</topic><topic>kidney transplant</topic><topic>Kidney transplantation</topic><topic>Kidney transplants</topic><topic>Liver transplantation</topic><topic>Monoclonal antibodies</topic><topic>Organ Transplantation - adverse effects</topic><topic>Pre-Exposure Prophylaxis</topic><topic>Prophylaxis</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Transplant Recipients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Jurdi, Ayman</creatorcontrib><creatorcontrib>Morena, Leela</creatorcontrib><creatorcontrib>Cote, Mariesa</creatorcontrib><creatorcontrib>Bethea, Emily</creatorcontrib><creatorcontrib>Azzi, Jamil</creatorcontrib><creatorcontrib>Riella, Leonardo V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Jurdi, Ayman</au><au>Morena, Leela</au><au>Cote, Mariesa</au><au>Bethea, Emily</au><au>Azzi, Jamil</au><au>Riella, Leonardo V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2022-12</date><risdate>2022</risdate><volume>22</volume><issue>12</issue><spage>3130</spage><epage>3136</epage><pages>3130-3136</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre‐exposure prophylaxis and 222 vaccine‐matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS‐CoV‐2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p < .001). In the tixagevimab/cilgavimab group, SOTRs who received the 150–150 mg dose had a higher incidence of breakthrough infections compared to those who received the 300–300 mg dose (p = .025). Adverse events were uncommon, occurring in 4% of our cohort and most were mild. There was no significant change in serum creatinine or liver chemistries in kidney and liver transplant recipients, respectively. In conclusion, we found that tixagevimab/cilgavimab use is safe and associated with a lower risk of breakthrough SARS‐CoV‐2 infection in vaccinated solid organ transplant recipients during the Omicron wave.
A retrospective matched cohort study shows that tixagevimab‐cilgavimab pre‐exposure prophylaxis in vaccinated solid organ transplant recipients is associated with a lower risk of breakthrough SARS‐CoV‐2 infection during the Omicron wave.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>35727916</pmid><doi>10.1111/ajt.17128</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7636-3196</orcidid><orcidid>https://orcid.org/0000-0002-7652-3399</orcidid><orcidid>https://orcid.org/0000-0002-6909-4645</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2022-12, Vol.22 (12), p.3130-3136 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9906353 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal Brief Communication COVID-19 Creatinine Disease prevention Humans Infections kidney transplant Kidney transplantation Kidney transplants Liver transplantation Monoclonal antibodies Organ Transplantation - adverse effects Pre-Exposure Prophylaxis Prophylaxis Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Transplant Recipients |
| title | Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T13%3A04%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tixagevimab/cilgavimab%20pre%E2%80%90exposure%20prophylaxis%20is%20associated%20with%20lower%20breakthrough%20infection%20risk%20in%20vaccinated%20solid%20organ%20transplant%20recipients%20during%20the%20omicron%20wave&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Al%20Jurdi,%20Ayman&rft.date=2022-12&rft.volume=22&rft.issue=12&rft.spage=3130&rft.epage=3136&rft.pages=3130-3136&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.17128&rft_dat=%3Cproquest_pubme%3E2679703086%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2744608548&rft_id=info:pmid/35727916&rfr_iscdi=true |